CAR T Cells: Off the Shelf and On the Mark

By |2021-09-16T02:41:51+00:00September 16th, 2021|

After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with some concrete limitations.

Go to Top